Singular Genomics Systems, Inc.

Equities

OMIC

US82933R1005

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
0.4144 USD +3.60% Intraday chart for Singular Genomics Systems, Inc. +6.26% -9.93%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating MT
Transcript : Singular Genomics Systems, Inc., Q4 2023 Earnings Call, Mar 18, 2024
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Posts Q4 Revenue $1.1M, vs. Street Est of $1.04M MT
Singular Genomics Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Singular Genomics Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Investors -2- DJ
Transcript : Singular Genomics Systems, Inc. - Special Call
Singular Genomics Systems, Inc. Showcases New G4X? Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4 Sequencing Platform CI
Singular Genomics Unveils G4X Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis CI
Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.85 From $0.95, Maintains Neutral Rating MT
Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023 CI
Singular Genomics Systems Expects 31% Growth in Q4 Revenue MT
Transcript : Singular Genomics Systems, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Posts Q3 Revenue $0.5M MT
Singular Genomics Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Fluent BioSciences Inc. Announces A Partnership with Singular Genomics CI
UBS Adjusts Singular Genomics Systems Price Target to $0.40 From $0.90, Maintains Neutral Rating MT
Singular Genomics Systems, Inc.(NasdaqGS:OMIC) dropped from S&P Global BMI Index CI
Transcript : Singular Genomics Systems, Inc. Presents at UBS MedTech, Tools and Genomics Summit 2023, Aug-16-2023 09:00 AM
UBS Adjusts Singular Genomics Systems Price Target to $0.90 From $1, Maintains Neutral Rating MT
Goldman Sachs Adjusts Price Target on Singular Genomics Systems to $1 From $1.15, Maintains Neutral Rating MT
Transcript : Singular Genomics Systems, Inc., Q2 2023 Earnings Call, Aug 09, 2023
Singular Genomics Systems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Reports Q2 Revenue $0.5M, vs. Street Est of $1.15M MT
Singular Genomics Appoints Marcia Eisenberg, Ph.D., to Board of Directors CI
Chart Singular Genomics Systems, Inc.
More charts
Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4 USD
Average target price
0.85 USD
Spread / Average Target
+112.50%
Consensus
  1. Stock Market
  2. Equities
  3. OMIC Stock
  4. News Singular Genomics Systems, Inc.
  5. Singular Genomics' G4 Sequencing Platform Joins 10x Genomics Compatible Partner Program